Save
New Antiangiogenic and Vascular Disrupting Agents and Their Combinations
ESGO eAcademy, Antonio Casado, 117566
RAS RAF MEK ERK Pathway
ESGO eAcademy, Cristiana Sessa, 117565
The Hudson Procedure
ESGO eAcademy, Gwenael Ferron, 117559
Potential Interest and Place of Uterine Transplantation in Gynaecologic Oncology
ESGO eAcademy, Yves Aubard, 117563
Lymph Node Dissection
ESGO eAcademy, Christian Marth, 117557
Oncologic Risk in Immuno-Suppressed Patients for Transplantation
ESGO eAcademy, Josep M. Grinyó, 117562
Peritoneal Stripping in Ovarian Cancer
ESGO eAcademy, Philipp Harter, 117556
First Results of Uterus Transplantation in Human
ESGO eAcademy, Pernilla Dahm-Kähler, 117561
How To Manage BRCA Mutated Patients?
ESGO eAcademy, Eric Pujade-Lauraine, 117551
Surgical and Systemic Treatment of Recurrences
ESGO eAcademy, Andreas Du Bois, 117550
Putting It All Together: the Impact of a Comprehensive, Standardised Enhanced Recovery Programme
ESGO eAcademy, Sean C. Dowdy, 117554
Systemic Therapy: from Chemotherapy to Targeted Therapy in Front Line and at Recurrence
ESGO eAcademy, Nicoletta Colombo, 117549
The Role of Nutrition in Perioperative Recovery
ESGO eAcademy, Federico Bozzetti, 117553
Surgical Treatment of Primary and Recurrent Ovarian Cancer
ESGO eAcademy, Émile Darai, 117548
How Anesthesia Can Improve Postoperative Recovery
ESGO eAcademy, Stephanie Suria, 117552
Horizon Scanning-Emerging Strategies for Recurrent Disease
ESGO eAcademy, Cristiana Sessa, 117546
Advanced Stage with Emphasis on Management of Patients with Positive Paraaortic Nodes
ESGO eAcademy, Christine Haie-Meder, 117537
Current Options for Relapsed Cervical Cancer
ESGO eAcademy, Jonathan A Ledermann, 117545
Surgical Management of Early Disease
ESGO eAcademy, Nicoletta Colombo, 117544
Rationale and Evidence for Tailored Approach to Early Stage Disease
ESGO eAcademy, David Cibula, 117536
Managing Early Relapse- Experimental Therapeutics
ESGO eAcademy, Cristiana Sessa, 117543
Current Choices for First Line Therapy
ESGO eAcademy, Jonathan A Ledermann, 117542
Surgery or Neoadjuvant Chemotherapy
ESGO eAcademy, Nicoletta Colombo, 117541
Update on Fertility Sparing Treatment
ESGO eAcademy, Nadeem Abu Rustum, 117535
Importance of Multidisciplinary Management of Gynaecological Cancers
ESGO eAcademy, Jonathan A Ledermann, 117540
Clinical Trial for Rare Tumours: List of Ongoing and Future Clinical Trials in EU and Unanswered Questions
ESGO eAcademy, Isabelle Ray-Coquard, 117530
Peritoneal Mesothelioma: Who Benefits from Radical Surgery?
ESGO eAcademy, Marcello Guaglio, 117533
Current Management of Appendiceal Neoplasia and Pseudomyxomes Peritonei
ESGO eAcademy, Sarah O'Dwyer, 117532
Organisation of Health Care Providers for the Treatment of Rare Peritoneal Malignancies: the French Way (Renape)
ESGO eAcademy, Olivier Glehen, 117531
Stage IV Ovarian Cancer: Prognosis of Patients with Exclusively Abdominal Wall Metastasis
ESGO eAcademy, Florian Heitz, 117712
The Impact of Lymph Node Dissection and Adjuvant Chemotherapy on Survival in Early-Stage Ovarian Cancer. Data of 3658 Patients
ESGO eAcademy, Marjolein Kleppe, 117525
Outcome of 129 Children After Antenatal Exposure to Cancer Treatment: Results of a Case-Control Study from the International Network on Cancer, Infertility and Pregnancy Registry
ESGO eAcademy, Frederic Amant, 117524
Prospective Evaluation of Lymphocele Incidence in Patients After Pelvic and Paraaortic Lymphadenectomy and Analysis of Risk Factors for Their Development
ESGO eAcademy, Michal Zikan, 117523
CA125 GC1G Criteria: Still Valid in the Era of Targeted and Immunologic Therapies
ESGO eAcademy, Bradley Monk, 116825
Response and Progression Criteria in Trials with Targeted Therapy. Recist and Variation
ESGO eAcademy, Cristiana Sessa, 116824
Response and Progression Criteria in Trials with Cytotoxic Agents: Recist and Variation
ESGO eAcademy, Andrés Poveda, 116822
Available Drugs Targeting the Known Altered Pathways in Ovarian Cancer
ESGO eAcademy, Cristiana Sessa, 116821
Potential Actionable Target Pathways in the Different Types of Ovarian Cancer
ESGO eAcademy, Iain McNeish, 116820
How to Measure the Benefit of Chemotherapy-Free Interval in a Trial with Maintenance Targeted Therapy? The Importance Combined Endpoints
ESGO eAcademy, Bradley Monk, 116819
How to Define Platinum-Resistance or Sensitivity after Several Lines of Treatment?
ESGO eAcademy, Jonathan A Ledermann, 116818
Debate: Platinum-Free Interval is Still a Valid Tool in Guiding Treatment Decision - CON
ESGO eAcademy, Sandro Pignata, 116817
Debate: Platinum-Free Interval is Still a Valid Tool in Guiding Treatment Decision - PRO
ESGO eAcademy, Mansoor Raza Mirza, 116816
Welcome and Introduction: The Changing Landscape of Clinical Trials in the Era of Targeted and Immunologic Therapies: Different Patient Selection, New Endpoints, New Responsible Criteria
ESGO eAcademy, Nicoletta Colombo, 116815
Possible role of robotics in ERAS
ESGO eAcademy, Eric Lambaudie, 105096
What is the place of sentinel procedures in gynecologic Oncology?
ESGO eAcademy, Rene H.M. Verheijen, 105095
Robotic single-site pelvic lymphadenectomy
ESGO eAcademy, Liliana Mereu, 106938
Endoscopic staging in early stage ovarian cancer
ESGO eAcademy, Eric Lambaudie, 106937
Key Lecture: Critical considerations on Robotic Surgery for the treatment of Endometrial Cancer
ESGO eAcademy, Angelo Maggioni, 105137
What progress is made and expected the coming decade in endoscopic (non-robotic) gynaecological surgery ?
ESGO eAcademy, Farr Nezhat, 105090
Single site robotic hysterectomy
ESGO eAcademy, Fatih Sendag, 105088
Compartment imaging with fluorescence
ESGO eAcademy, K. Rainer Kimmig, 105087
New robots and implementation
ESGO eAcademy, Rene H.M. Verheijen, 105086
Paraaortic lymphadenectomy and surgical approach
ESGO eAcademy, Fabrice Narducci, 105085
Robotic radical trachelectomy
ESGO eAcademy, M. Faruk Kose, 105084
Robotic-assisted radical hysterectomy: oncology outcomes
ESGO eAcademy, Vanna Zanagnolo, 105083
Key lecture: Radical hysterectomy: Overview of the different techniques of parametrial dissection
ESGO eAcademy, K. Rainer Kimmig, 105082
Abstracts for Meetings
ESGO eAcademy, Sean Kehoe, 108687
Clinical Trials
ESGO eAcademy, Sean Kehoe, 108688
Journals for Gynaecological Oncology
ESGO eAcademy, Sean Kehoe, 108689
Other Publications
ESGO eAcademy, Sean Kehoe, 108690
The Oral Presentation
ESGO eAcademy, Sean Kehoe, 108691
Constructing a Paper
ESGO eAcademy, Christina Fotopoulou, 108692
The Poster Presentation
ESGO eAcademy, Christina Fotopoulou, 108693
Why Are Papers Rejected?
ESGO eAcademy, Christina Fotopoulou, 108694
Statistical Basic Facts
ESGO eAcademy, Mariana Díaz Almirón, 108695
European Reference Network
ESGO eAcademy, Francois Golfier, 99309
Future Perspectives in Gestational Trophoblastic Disease
ESGO eAcademy, Leon Massuger, 99308
PSTT/ETT
ESGO eAcademy, Barry Hancock, 99307
When EMACO Does Not Cure
ESGO eAcademy, Michael Seckl, 99305
Case Report Hi Dose
ESGO eAcademy, Kirsty Balachandran, 99304
Treatment of High Risk Gestational Trophoblastic Disease
ESGO eAcademy, John Tidy, 99303
Case: High Risk Gestational Trophoblastic Disease
ESGO eAcademy, Mireille Vree, 99302
Treatment of Low Risk Gestational Trophoblastic Disease
ESGO eAcademy, John Coulter, 99301
Case: MTX Resistance
ESGO eAcademy, Sam Schoenmakers, 99300
Histologic and Immunohistochemic Features of Trophoblastic Disease
ESGO eAcademy, Sophie Patrier, 99299
Case Report Pathology
ESGO eAcademy, Gwendoline Side-Pfennig, 99298
HCG in Gestational Trophoblastic Disease
ESGO eAcademy, Teun van Herwaarden, 99295
Case: Clinical Consequences of Different hCG Assays
ESGO eAcademy, Yalck Eysbouts, 99294
History of Gestational Trophoblastic Disease
ESGO eAcademy, Rene H.M. Verheijen, 99293
Immunotherapy Represents the Future for Ovarian Cancer
ESGO eAcademy, Bradley Monk, 96876
Immunotherapy Has Never Worked and Will Never Work in Ovarian Cancer
ESGO eAcademy, Eric Pujade-Lauraine, 96875
How To Negotiate Support with Pharma Companies for Sponsored Trials
ESGO eAcademy, Andreas Du Bois, 96873
How To Write a Grant for Academic Trials (Investigator-Initiated)
ESGO eAcademy, Sandro Pignata, 96872
The Hurdles of Conducting Trials across Different Countries: Focus on EU Regulations and Differences Which May Constitute Barriers to Run an ENGOT Trial
ESGO eAcademy, Jacobus Pfisterer, 96871
The Challenge of Initiating a National Cooperative Trial Group: Tricks and Tips
ESGO eAcademy, Mansoor Raza Mirza, 96870
Outside EU Regulations: Activating a Study in Switzerland
ESGO eAcademy, Cristiana Sessa, 96983
Managing Depression in Cancer Patients
ESGO eAcademy, Madeline Li & Gary Rodin, 63587
Reversing Mutated p53 to Wild Type
ESGO eAcademy, Sevilay Altintas, 63068
Inhibiting the Gain-of-Function of Mutated p53
ESGO eAcademy, Nicole Concin, 63067
Why Signatures Miss the Goal in Ovarian Cancer
ESGO eAcademy, MICHAEL BIRRER, 63066
Why Signatures Are the Best Way to Identify Subgroups in Ovarian Cancer
ESGO eAcademy, Charlie Gourley, 63065
The Tricky Decision to Allow Cross-Over or Not in a Trial
ESGO eAcademy, Bradley J. Monk, 63064
Funding Options, Legal Aspect and Insurance Hurdles, How To Select Centers for Surgical Trials?
ESGO eAcademy, Jacobus Pfisterer, 63060
What Are the Endpoints and Do We Have the Right Questionnaires for QOL? What Are the Open Questions in Relapse Ovarian Cancer?
ESGO eAcademy, Philipp Harter, 63061
Anaesthetic complications
ESGO eAcademy, Oliver Groll, 63116
Injury of the gastrointestinal tract
ESGO eAcademy, Gökhan Yagci, 63094
Robotic debulking surgery
ESGO eAcademy, Javier Magrina, 63093
EU reimbursement update and the role of medical expertise in Driving Dr.G change
ESGO eAcademy, Susanne Habetha, 63134
Chance of cost reduction and increase of efficiency in robotic surgery
ESGO eAcademy, Petur Reynisson, 63133
Cost analysis in endometrial cancer patients
ESGO eAcademy, Frederic Goffin, 63132

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings